| 5.74 -0.29 (-4.81%) | 07-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.56 | 1-year : | 8.83 |
| Resists | First : | 6.47 | Second : | 7.56 |
| Pivot price | 6.03  |
|||
| Supports | First : | 5.39 | Second : | 4.73 |
| MAs | MA(5) : | 6.13 |
MA(20) : | 5.86 |
| MA(100) : | 5.44 |
MA(250) : | 4.81 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 56.3 |
D(3) : | 73.5 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 7 | Low : | 2.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SVRA ] has closed above bottom band by 13.6%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.93 - 5.97 | 5.97 - 5.99 |
| Low: | 5.58 - 5.62 | 5.62 - 5.66 |
| Close: | 5.68 - 5.75 | 5.75 - 5.8 |
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
Sun, 28 Jun 2026
Levi & Korsinsky Notifies Savara Inc. (SVRA) Investors - Lead Plaintiff Deadline on November 7, 2025 - The National Law Review
Fri, 26 Jun 2026
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
Mon, 22 Jun 2026
[144] Savara Inc SEC Filing - Stock Titan
Mon, 22 Jun 2026
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Mon, 08 Jun 2026
Savara Announces Chief Financial and Administrative Officer Transition - Business Wire
Wed, 27 May 2026
Savara: The Rare Disease Funnel Is Becoming A Commercial Asset (NASDAQ:SVRA) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 205 (M) |
| Shares Float | 130 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 104.2 (%) |
| Shares Short | 32,030 (K) |
| Shares Short P.Month | 30,190 (K) |
| EPS | -0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -40.6 % |
| Return on Equity (ttm) | -80 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.4 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -107 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -10.25 |
| PEG Ratio | 0 |
| Price to Book value | 8.31 |
| Price to Sales | 0 |
| Price to Cash Flow | -11.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|